Close Menu
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations

November 21, 2026

The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India

November 21, 2026

‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam

November 21, 2026
Facebook X (Twitter) Instagram
Trending
  • Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations
  • The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India
  • ‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam
  • HydraSure’s Gen Z Team Turns GTA VI Launch Day Into a Giveaway – Planned and Live in 24 Hours
  • Kingston Debuts at Embedded World India, Deepening Its B2B Push in India’s Enterprise and Industrial Markets
  • Heart and Lung Transplant Recipients Share Stories of a New Life at KIMS Patient Meet in Indore
  • Rahul Gupta: 10 Years of Selfless Service, Compassion and Humanity
  • Vijay Arora Announces Sataack 50, a Professional Tennis-Ball Cricket League for Men and Women
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World
The Startup StoryThe Startup Story
Home»Business»Sudarshan Pharma Industries to Acquire 9.5% Stake in US-Based MedTherapy Biotech
Business

Sudarshan Pharma Industries to Acquire 9.5% Stake in US-Based MedTherapy Biotech

Arjun SinghBy Arjun SinghSeptember 7, 2026No Comments
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Mumbai (Maharashtra) [India], September 7: BSE-listed Sudarshan Pharma Industries Ltd [BSE Scrip Code: 543828, Trading Symbol: SUDARSHAN, ISIN: INE00TV01023] has announced its first major overseas biotech acquisition.

In a disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company informed exchanges that its Board of Directors at its meeting held today – 5th September 2026 between 4:30 pm and 5:00 pm – has approved the acquisition of 24,23,675.64 equity shares of Common Stock, par value US$0.0001 per share, of MedTherapy Biotechnology Inc., USA.

The acquisition represents 9.50% of the issued and outstanding share capital of the target company. The consideration will be paid in cash in US Dollars, with the price based on valuation as per prevailing valuation norms.

Promoters to co-invest

Alongside the company, its promoters will also acquire a stake in the same target:

  • Mr. Hemal Mehta, Chairman & Managing Director: 3,82,685.63 shares (1.50%)
  • Mr. Sachin Mehta, Joint Managing Director: 3,82,685.63 shares (1.50%)

The company clarified that the transaction does not fall within related party transactions and will be done at arm’s length.

Legal and commercial due diligence will be concluded before closure, with FEMA compliances to be addressed.

Target Snapshot: MedTherapy Biotechnology Inc.

According to Annexure-A filed by the company:

Name: MedTherapy Biotechnology Inc. (“MedTherapy Biotech”), a corporation incorporated under the laws of the State of Delaware, USA

Business: Boston-based global Cancer Cell & Gene Therapy Company founded in 2018 by experts from Harvard and former Novartis executives. It operates as an end-to-end, integrated CAR-T Cell CDMO, with a commercial-scale GMP manufacturing facility in New Delhi, India and a technology development site in Boston, USA.

Mission: Founded with a mission to make CAR-T cell therapy affordable and accessible so that almost every cancer patient would be able to afford it.

Strategic Rationale

Sudarshan Pharma listed three key objects for the 9.5% acquisition:

  1. Enter the U.S. market and establish a presence there.
  2. Access the customer base, contracts, and distribution network.
  3. Expand into new products and services.

The move marks a diversification beyond its main line of business into high-value advanced cell and gene therapy CDMO services.

Regulatory Path & Timeline

The company said governmental approval required is from the Reserve Bank of India under Foreign Exchange Management Act, 1999 and the Foreign Exchange Management (Overseas Investment) Rules, Regulations and Directions, 2022, as may be amended from time to time – under the automatic route.

Indicative time period for completion: On or before 31st March 2027.

The company has requested BSE to take the disclosure on record.

Business
Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
Arjun Singh
  • Website

Related Posts

The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India

November 21, 2026

Kingston Debuts at Embedded World India, Deepening Its B2B Push in India’s Enterprise and Industrial Markets

November 21, 2026

HRH Next Services Limited Reports H1 FY27 Results

November 21, 2026

Comments are closed.

Top Posts

Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations

November 21, 2026

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020

Make your own inhouse library and learn

February 22, 2020
Don't Miss
National

Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations

By Arjun SinghNovember 21, 2026

Kharagpur (West Bengal) [India], November 21: Pan IIT Alumni India has welcomed Prime Minister Narendra…

The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India

November 21, 2026

‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam

November 21, 2026

HydraSure’s Gen Z Team Turns GTA VI Launch Day Into a Giveaway – Planned and Live in 24 Hours

November 21, 2026
Most Popular

Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations

November 21, 2026

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020
Categories
  • Business
  • Business News
  • Education
  • Entertainment
  • Finance
  • Health
  • Lifestyle
  • National
  • Press Release
  • Sports
  • Technology
  • Uncategorized
  • World
Our Picks

Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations

November 21, 2026

The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India

November 21, 2026

‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam

November 21, 2026

Type above and press Enter to search. Press Esc to cancel.